Development of DDS for mRNA therapeutics: Polyplex nanomicelle

Abstract

mRNA therapeutics is defined as a new type of nucleic acid medicine by direct administration of synthesized mRNA into the body for therapeutic and prophylactic purposes. Since mRNA is extremely unstable outside the cells, DDS plays a crucial role for delivering the mRNA into thetarget cells in the body. LNPs have been most frequentlySused for mRNA delivery, however, it is still difficult to target various tissues and organs other than the liver. We are developing an original DDS, polyplex nanomicelle, which is advantageous in its excellent capacity of tissue penetration after local administration, as well as the low toxicity due to the biodegradability of the nanomicelle. In this article, I wouldDDlike to introduce the system of polyplex nanomicelle, and the recent studies using the nanomicelles for administering mRNA therapeutics for disease treatment.